ArticleNature communications2020
Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- ERK autoinhibition mechanism informs a drug combination strategy.Protein science : a publication of the Protein Society · 2026Article
- GCN5-ERK lactylation-phosphorylation loop amplifies lactate-driven cancer progression.Nature chemical biology · 2026Article
- Molecular Frameworks for ERK1/2 Inhibition: Lessons from Synthetic and SAR Explorations.ACS omega · 2025Review
- Identification and Characterization of ERK2 Dimerization Inhibitors by Integrated In Silico and In Vitro Screening.International journal of molecular sciences · 2025Article
- ERK Allosteric Activation: The Importance of Two Ordered Phosphorylation Events.Journal of molecular biology · 2025Article
- Proteomic surveys of the mouse heart unveil cardiovascular responses to nitric oxide/cGMP signaling deficiencies.Communications biology · 2025Article
- Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro.Molecules (Basel, Switzerland) · 2025Article
- Article
- Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation.The oncologist · 2024Review
- Cardiac recovery from pressure overload is not altered by thyroid hormone status in old mice.Frontiers in endocrinology · 2024Article
- MEK inhibitors: a promising targeted therapy for cardiovascular disease.Frontiers in cardiovascular medicine · 2024Review
- TLR7 Agonists Modulate the Activation of Human Conjunctival Epithelial Cells Induced by IL-1β via the ERK1/2 Signaling Pathway.Inflammation · 2023Article
- Review
- Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic opportunities.Journal of molecular and cellular cardiology plus · 2023Review
- The activation of MActa biochimica et biophysica Sinica · 2022Article
- ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses.Endocrinology · 2022Review
- The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.Archives of toxicology · 2022Article
- CARS Imaging Advances Early Diagnosis of Cardiac Manifestation of Fabry Disease.International journal of molecular sciences · 2022Article
- Harnessing RKIP to Combat Heart Disease and Cancer.Cancers · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 12 institutions in 1 country.
Angela Tomasovic *Institute of Pharmacology and Toxicology, University of Würzburg, 97078, Würzburg, Germany.
Theresa Brand *Institute of Pharmacology and Toxicology, University of Würzburg, 97078, Würzburg, Germany.
Constanze Schanbacher *Institute of Pharmacology and Toxicology, University of Würzburg, 97078, Würzburg, Germany.
Sofia KramerInstitute of Pharmacology and Toxicology, University of Würzburg, 97078, Würzburg, Germany.
Martin W HümmertInstitute of Pharmacology and Toxicology, University of Würzburg, 97078, Würzburg, Germany.ORCID http://orcid.org/0000-0002-5928-2343
Patricio GodoyIfADo-Leibniz Research Centre for Working Environment and Human Factors at the Technical University Dortmund, 44139, Dortmund, Germany.
Wolfgang Schmidt-HeckLeibniz Institute for Natural Product Research and Infection Biology -Hans Knoell Institute-, 07745, Jena, Germany.
Peter NordbeckComprehensive Heart Failure Center, 97078, Würzburg, Germany.ORCID http://orcid.org/0000-0002-2560-4068
Jonas LudwigDepartment of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058, Erlangen, Germany.
Susanne HomannInstitute of Pharmacology and Toxicology, University of Würzburg, 97078, Würzburg, Germany.
Armin WiegeringDepartment of General, Visceral, Transplant, Vascular and Pediatric Surgery, University Hospital of Würzburg, 97080, Würzburg, Germany.ORCID http://orcid.org/0000-0001-7777-0909
Timur ShaykhutdinovLeibniz-Institut für Analytische Wissenschaften - ISAS-e.V., 12489, Berlin, Germany.
Christoph KratzLeibniz-Institut für Analytische Wissenschaften - ISAS-e.V., 12489, Berlin, Germany.ORCID http://orcid.org/0000-0002-4046-0760
Ruth KnüchelInstitute of Pathology, University Hospital Aachen, RWTH Aachen, 52074, Aachen, Germany.
Hans-Konrad Müller-HermelinkInstitute of Pathology, University of Würzburg, 97080, Würzburg, Germany.
Andreas RosenwaldInstitute of Pathology, University of Würzburg, 97080, Würzburg, Germany.
Norbert FreyDepartment of Internal Medicine III, University of Kiel, 24105, Kiel, Germany.
Jutta EichlerDepartment of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058, Erlangen, Germany.
Dobromir DobrevInstitute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, 45147, Essen, Germany.
Ali El-ArmoucheDepartment of Pharmacology and Toxicology, TU Dresden, 01307, Dresden, Germany.
Jan G HengstlerIfADo-Leibniz Research Centre for Working Environment and Human Factors at the Technical University Dortmund, 44139, Dortmund, Germany.ORCID http://orcid.org/0000-0002-1427-5246
Oliver J MüllerDepartment of Internal Medicine III, University of Kiel, 24105, Kiel, Germany.ORCID http://orcid.org/0000-0001-8223-2638
Karsten HinrichsLeibniz-Institut für Analytische Wissenschaften - ISAS-e.V., 12489, Berlin, Germany.ORCID http://orcid.org/0000-0002-6580-7791
Friederike CuelloInstitute of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Alma ZerneckeInstitute of Experimental Biomedicine, University Hospital Würzburg, University of Würzburg, 97080, Würzburg, Germany.
Kristina LorenzInstitute of Pharmacology and Toxicology, University of Würzburg, 97078, Würzburg, Germany. lorenz@toxi.uni-wuerzburg.de.ORCID http://orcid.org/0000-0002-5747-2207
University of Würzburg · DELeibniz Institute for Analytical Sciences - ISAS · DEChristian-Albrechts-Universität zu Kiel · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DETU Dortmund University · DEComprehensive Cancer Center Mainfranken · DELeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DETechnische Universität Dresden · DEUniversität Hamburg · DEUniversitätsklinikum Aachen · DEUniversitätsklinikum Würzburg · DEWest German Heart and Vascular Center Essen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of extracellular signal-regulated kinases (ERK1/2) is linked to several diseases including heart failure, genetic syndromes and cancer. Inhibition of ERK1/2, however, can cause severe cardiac side-effects, precluding its wide therapeutic application. ERK
Indexed as
CardiotoxicityDimerizationMAP Kinase Signaling SystemAnimalsCell Culture TechniquesCell-Penetrating PeptidesColonic NeoplasmsDrug Delivery SystemsExtracellular Signal-Regulated MAP KinasesHeart FailureHumansLung NeoplasmsMiceMice, Inbred C57BLMolecular MedicineRatsCell-Penetrating PeptidesExtracellular Signal-Regulated MAP Kinasespenetratin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.